Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2022-04-27 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
年度股东大会通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2021 Annual General Meeting (AGM) of Jiangsu Sihuan Bioengineering Co., Ltd. It details the meeting date, voting procedures, agenda items including the 2021 annual report, financial statements, profit distribution plan, remuneration, and audit firm appointment. It also includes proxy forms and voting instructions. The document is not the annual report itself but a formal announcement and invitation to the AGM with agenda and voting details. The document length is 3413 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2022-04-27 Chinese
江苏四环生物股份有限公司独立董事2021年度述职报告（钱国双）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021 by an independent director of Jiangsu Sihuan Bio Co., Ltd. It details the director's attendance at board meetings, independent opinions on various board resolutions, supervisory activities, and efforts to protect investor rights. The content focuses on the director's duties and governance oversight rather than financial results or audit opinions. It is a report on board/management activities and governance rather than a financial report or announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1534 characters), but it is a substantive report, not a mere announcement or certification, so it is not RPA or RNS.
2022-04-27 Chinese
监事会关于公司2021年度内部控制自我评价的审议意见
Regulatory Filings Classification · 95% confidence The document is a statement from the supervisory board regarding the company's 2021 internal control self-evaluation report. It references the internal control evaluation report but does not contain the full report or detailed financial data. The document is short (228 characters) and serves as an opinion or certification on the internal control report, not the report itself. According to the Certification Rule, such documents are classified as Regulatory Filings (RNS).
2022-04-27 Chinese
会计师事务所对非标意见涉及事项专项说明
Regulatory Filings
2022-04-27 Chinese
江苏四环生物股份有限公司关于2021年度计提资产减值准备及核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding the 2021 annual asset impairment provisions and asset write-offs. It details the accounting policies, impairment testing, and specific figures related to asset impairment and write-offs for the fiscal year ending December 31, 2021. The document includes detailed financial data on impairment provisions and explanations of the methods used, as well as the impact on the company's net profit. It also mentions that the impairment provisions have been audited by an accounting firm. The document is relatively short (2399 characters) and is focused on a specific accounting event rather than a full annual report or interim report. It is not a full financial report but a regulatory announcement about asset impairment and write-offs. This fits best under the category of Regulatory Filings (RNS), as it is a compliance disclosure related to accounting estimates and asset impairment, not a full audit report or annual report. It is not a report publication announcement since it contains substantive financial data and explanations, but it is not a full financial report either.
2022-04-27 Chinese
江苏四环生物股份有限公司独立董事2021年度述职报告（徐小娟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2021 from Jiangsu Sihuan Bio Co., Ltd. It details the independent director's duties, attendance at board meetings, opinions on various board resolutions, and efforts to protect investor rights. It is a narrative report on the independent director's activities and oversight during the year, rather than a full annual report or financial statement. It does not contain financial data or audit results but focuses on governance and supervisory roles. This type of document fits best under Board/Management Information (MANG), as it relates to board member activities and governance oversight rather than financial reporting or regulatory filings.
2022-04-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.